Literature DB >> 2526377

Back pain after Harrington rod instrumentation for idiopathic scoliosis.

G Fabry1, J Van Melkebeek, E Bockx.   

Abstract

The purpose of this study is to compare preoperative and postoperative back pain problems in 182 patients operated on for idiopathic scoliosis. Preoperatively 32% of the patients presented with back pain, increasing to 66% postoperatively. Minor degrees of back pain increased (from 45 to 65%) and more severe complaints decreased (from 55 to 35%). Moderate to severe back pain increases from 0 to 46%, together with lower hook placement from L1 to L5. It is concluded that, ideally, the lower limit of the fusion should not go beyond L1 or L2. Lower fusions are prone to give more back pain, with major problems, however, only in a minority of cases (7% in fusions to L4-L5).

Entities:  

Mesh:

Year:  1989        PMID: 2526377     DOI: 10.1097/00007632-198906000-00015

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  3 in total

1.  Optimizing the fusion level for lenke 5C adolescent idiopathic scoliosis: is the S-line a validated and reproducible tool to predict coronal decompensation?

Authors:  Tianyuan Zhang; Shibin Shu; Wenting Jing; Qi Gu; Zezhang Zhu; Zhen Liu; Yong Qiu; Xu Sun; Bin Wang; Hongda Bao
Journal:  Eur Spine J       Date:  2021-03-04       Impact factor: 3.134

2.  The analysis of progression of disc degeneration in distal unfused segments and evaluation of long-term functional outcome in adolescent idiopathic scoliosis patients undergoing long-segment instrumented fusion.

Authors:  Sridhar Jakkepally; Vibhu Krishnan Viswanathan; Ajoy Prasad Shetty; Swapnil Hajare; Rishi Mukesh Kanna; S Rajasekaran
Journal:  Spine Deform       Date:  2021-10-20

3.  Pain and disability following fusion for idiopathic adolescent scoliosis: prevalence and associated factors.

Authors:  Teresa Bas; Nuria Franco; Paloma Bas; Jose Luis Bas
Journal:  Evid Based Spine Care J       Date:  2012-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.